Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Application of liposomes in drug development--focus on gastroenterological targets.

Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC.

Int J Nanomedicine. 2013;8:1325-34. doi: 10.2147/IJN.S42153. Epub 2013 Apr 8. Review.

2.

Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.

Chang HI, Yeh MK.

Int J Nanomedicine. 2012;7:49-60. doi: 10.2147/IJN.S26766. Epub 2011 Dec 30. Review.

3.

Challenges in development of targeted liposomal therapeutics.

Sawant RR, Torchilin VP.

AAPS J. 2012 Jun;14(2):303-15. doi: 10.1208/s12248-012-9330-0. Epub 2012 Mar 14. Review.

4.

Liposomes in biology and medicine.

Schwendener RA.

Adv Exp Med Biol. 2007;620:117-28. Review.

PMID:
18217339
5.

Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy.

Kumar P, Gulbake A, Jain SK.

Crit Rev Ther Drug Carrier Syst. 2012;29(5):355-419. Review.

PMID:
22876808
6.

Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Kesisoglou F, Zhou SY, Niemiec S, Lee JW, Zimmermann EM, Fleisher D.

Pharm Res. 2005 Aug;22(8):1320-30. Epub 2005 Aug 3.

PMID:
16078142
7.

Liposomes and nanotechnology in drug development: focus on ocular targets.

Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N.

Int J Nanomedicine. 2013;8:495-503. doi: 10.2147/IJN.S30725. Epub 2013 Feb 14. Review.

8.

Promising targets and drugs in development for colorectal cancer.

Thompson C, Leong S, Messersmith W.

Semin Oncol. 2011 Aug;38(4):588-97. doi: 10.1053/j.seminoncol.2011.05.013. Review.

PMID:
21810518
9.

Liposomal drug delivery systems: from concept to clinical applications.

Allen TM, Cullis PR.

Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. Review.

PMID:
23036225
10.

Liposomal drug delivery systems: an update review.

Samad A, Sultana Y, Aqil M.

Curr Drug Deliv. 2007 Oct;4(4):297-305. Review.

PMID:
17979650
11.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
12.

[Application of novel drug delivery system, fusogenic liposome, for cancer therapy].

Kunisawa J, Mayumi T.

Gan To Kagaku Ryoho. 2001 May;28(5):577-83. Review. Japanese.

PMID:
11383204
13.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
14.

Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.

Flaten GE, Chang TT, Phillips WT, Brandl M, Bao A, Goins B.

J Liposome Res. 2013 Mar;23(1):70-81. doi: 10.3109/08982104.2012.742537. Epub 2012 Dec 5.

PMID:
23210622
15.

Therapeutic uses of antioxidant liposomes.

Stone WL, Smith M.

Mol Biotechnol. 2004 Jul;27(3):217-30. Review.

PMID:
15247495
16.
17.

Developments in liposomal drug delivery systems.

Maurer N, Fenske DB, Cullis PR.

Expert Opin Biol Ther. 2001 Nov;1(6):923-47. Review.

PMID:
11728226
19.

Multiparticulate systems in the treatment of inflammatory bowel disease.

Lamprecht A.

Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):137-44. Review.

PMID:
14561166
20.

Lysolipid containing liposomes for transendothelial drug delivery.

Koklic T, Trancar J.

BMC Res Notes. 2012 Apr 10;5:179. doi: 10.1186/1756-0500-5-179.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk